Publication:
Tafenoquine for the prevention of Plasmodium vivax malaria relapse

Simple item page
dc.contributor.authorJames A. Watsonen_US
dc.contributor.authorNarimane Nekkaben_US
dc.contributor.authorMichael Whiteen_US
dc.contributor.otherFaculty of Tropical Medicine, Mahidol Universityen_US
dc.contributor.otherNuffield Department of Medicineen_US
dc.contributor.otherInstitut Pasteur, Parisen_US
dc.date.accessioned2022-08-04T08:50:30Z
dc.date.available2022-08-04T08:50:30Z
dc.date.issued2021-05-01en_US
dc.identifier.citationThe Lancet Microbe. Vol.2, No.5 (2021), e175-e176en_US
dc.identifier.doi10.1016/S2666-5247(21)00062-8en_US
dc.identifier.issn26665247en_US
dc.identifier.other2-s2.0-85105303835en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/77295
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85105303835&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleTafenoquine for the prevention of Plasmodium vivax malaria relapseen_US
dc.typeLetteren_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85105303835&origin=inwarden_US

Files

Collections

Scopus 2021